我平仓了2手$SMM_老虎社区_美港股上老虎

盲炳
06-14

我平仓了2手$SMMT 20250613 19.5 PUT$ ,我看好Summit Therapeutics(SMMT.US)的长期潜力。从核心逻辑看，其与康方生物合作的ivonescimab在肺癌关键3期试验中实现无进展生存期（PFS）的统计学显著改善，打破了EGFR突变耐药患者领域抗PD-1单抗长期未突破的困境，数据扎实且具备临床突破性；中美双市场联动布局更是亮点——中国已获批奠定商业化基础!

SMMT PUT

06-14 16:06

US20250613 19.5

方向	价格 \| 数量	已实现盈亏
买入平仓	0.00 2手	+100.00% 已结束

Summit Therapeutics PLC

# 掘金交易单：你关注了哪些厉害的“宝藏投资者”？

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":445916832539384,"tweetId":"445916832539384","gmtCreate":1749890792005,"gmtModify":1749897390922,"author":{"id":4160043317841132,"idStr":"4160043317841132","authorId":4160043317841132,"authorIdStr":"4160043317841132","name":"盲炳","avatar":"https://static.tigerbbs.com/09e35dfa13bb37ecf43f9395b43c908f","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":8,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":22,"starInvestorFlag":false},"themes":[{"themeId":"252184c6e50244f89f5dd53d31dd9b7e","categoryId":"15075ea16ca14ca2b61a3fab20c8c6a9","name":"掘金交易单：你关注了哪些厉害的“宝藏投资者”？","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":252184c6e50244f89f5dd53d31dd9b7e}&rnconfig={\"headerBarHidden\": true}","description":"欢迎来到【交易分享】功能专区。在这里，你能看到老虎社区众多“大神”的订单分享，挖掘意想不到的交易机会，也欢迎虎友们互相推荐、安利自己发现的“宝藏投资者”哦！","image":"https://static.tigerbbs.com/e496e574dd744490c7b4f7959f83f5a4"}],"images":[],"coverImages":[],"html":"<html><head></head><body>我平仓了2手<a href=\"https://laohu8.com/OPT/SMMT 20250613 19.5 PUT\">$SMMT 20250613 19.5 PUT$&nbsp;</a>,我看好Summit Therapeutics(SMMT.US)的长期潜力。从核心逻辑看，其与康方生物合作的ivonescimab在肺癌关键3期试验中实现无进展生存期（PFS）的统计学显著改善，打破了EGFR突变耐药患者领域抗PD-1单抗长期未突破的困境，数据扎实且具备临床突破性；中美双市场联动布局更是亮点——中国已获批奠定商业化基础!</body></html>","htmlText":"<html><head></head><body>我平仓了2手<a href=\"https://laohu8.com/OPT/SMMT 20250613 19.5 PUT\">$SMMT 20250613 19.5 PUT$&nbsp;</a>,我看好Summit Therapeutics(SMMT.US)的长期潜力。从核心逻辑看，其与康方生物合作的ivonescimab在肺癌关键3期试验中实现无进展生存期（PFS）的统计学显著改善，打破了EGFR突变耐药患者领域抗PD-1单抗长期未突破的困境，数据扎实且具备临床突破性；中美双市场联动布局更是亮点——中国已获批奠定商业化基础!</body></html>","text":"我平仓了2手$SMMT 20250613 19.5 PUT$ ,我看好Summit Therapeutics(SMMT.US)的长期潜力。从核心逻辑看，其与康方生物合作的ivonescimab在肺癌关键3期试验中实现无进展生存期（PFS）的统计学显著改善，打破了EGFR突变耐药患者领域抗PD-1单抗长期未突破的困境，数据扎实且具备临床突破性；中美双市场联动布局更是亮点——中国已获批奠定商业化基础!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/445916832539384","repostId":0,"isVote":1,"tweetType":1,"viewCount":246,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["SMMT","PFS"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":true,"orderData":{"uuid":"4160043317841132","orderId":"39451252631292928","kind":"TRADE","symbol":"SMMT","secType":"OPT","symbolHtmlTag":"<a href=\"https://laohu8.com/OPT/SMMT 20250613 19.5 PUT\">$SMMT 20250613 19.5 PUT$&nbsp;</a>","symbolHtmlTagHref":"https://laohu8.com/OPT/SMMT 20250613 19.5 PUT","symbolName":"SMMT 20250613 19.5 PUT","market":"US","action":"BUY","currency":"USD","symbolLogo":"","showFilledQuantity":true,"nameCN":"Summit Therapeutics PLC","orderType":"LMT","right":"PUT","strike":"19.5","expiry":"20250613","filledQuantityFinal":2,"avgFillPrice":0,"createTime":1749888371,"filledQuantity":"2","filledQuantityScale":"0","openFlag":false,"side":"DEBIT","contractMajorDescription":"SMMT PUT","contractExtraDescription":"20250613 19.5","legs":[],"completedFlag":true,"orderPnl":{"realizedPnlPercent":1,"realizedPnlByAveragePercent":1},"quickOrderFlag":false},"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":["订单分享帖"],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":274,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}